Boston Life Sciences to Host 2007 1st Quarter Conference Call
10 May 2007 - 12:00AM
PR Newswire (US)
HOPKINTON, Mass., May 9 /PRNewswire-FirstCall/ -- Boston Life
Sciences, Inc. (NASDAQ:BLSI) today announced that they will host a
conference call on Wednesday, May 16th, 2007 at 10:00am EDT to
review the first quarter of 2007 and discuss other matters related
to the Company. To access the conference call, please dial (888)
208-1812 for domestic and (719) 457-2654 international. The code
for this conference call is 9475655. Please dial in 5 to 10 minutes
prior to the scheduled start time. A replay of the call will be
posted on the Investor Relations section of the website,
http://www.bostonlifesciences.com/, within 48 hours following the
conference call and will be available through Wednesday, May 30th,
2007. About Boston Life Sciences, Inc. Boston Life Sciences, Inc.
(BLSI) is engaged in the research and clinical development of
diagnostic and therapeutic products for central nervous system
(CNS) disorders. Cethrin(R), a recombinant-protein-based drug
designed to promote nerve repair after acute spinal cord injury,
has reported positive interim results in a Phase I/IIa clinical
trial. ALTROPANE(R) molecular imaging agent is in Phase III
clinical trials for the diagnosis of Parkinson's Disease (PD). The
company's research and pre-clinical CNS programs include Inosine
for the treatment of spinal cord injury and stroke, a DAT blocker
for the treatment of Parkinson's disease, and a second generation
technetium-based molecular imaging agent for PD and ADHD. BLSI's
current research collaborations include Harvard Medical School and
Children's Hospital Boston. Safe Harbor The foregoing release
contains certain forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Forward-
looking statements include statements regarding Boston Life
Sciences' future expectations, beliefs, intentions, goals,
strategies, plans or prospects regarding the future, including the
development and commercialization of ALTROPANE and Cethrin, the
prospects of the Company's CNS therapeutics program, the Company's
strategies to develop and commercialize axon regeneration
technologies and the breadth of the Company's technologies and
intellectual property portfolio. Forward-looking statements can be
identified by terminology such as "anticipate," "believe," "could,"
"could increase the likelihood," "estimate," "expect," "intend,"
"is planned," "may," "should," "will," "will enable," "would be
expected," "look forward," "may provide," "would" or similar terms,
variations of such terms or the negative of those terms. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors including those risks,
uncertainties and factors referred to in the Company's Annual
Report on Form 10-K for the year ended December 31, 2006 filed with
the Securities and Exchange Commission under the section "Risk
Factors," as well as other documents that may be filed by Boston
Life Sciences from time to time with the Securities and Exchange
Commission. As a result of such risks, uncertainties and factors,
the Company's actual results may differ materially from any future
results, performance or achievements discussed in or implied by the
forward-looking statements contained herein. Boston Life Sciences
is providing the information in this press release as of this date
and assumes no obligations to update the information in this press
release. Contact: Sharon Correia -- 508-497-2360 ext 224 Boston
Life Sciences, Inc. DATASOURCE: Boston Life Sciences, Inc. CONTACT:
Sharon Correia of Boston Life Sciences, Inc., +1-508-497-2360 ext
224, Web site: http://www.bostonlifesciences.com/
Copyright
Boston Life Sciences (NASDAQ:BLSI)
Historical Stock Chart
From Apr 2024 to May 2024
Boston Life Sciences (NASDAQ:BLSI)
Historical Stock Chart
From May 2023 to May 2024